Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome

Gottardi, Andrea De; Hilleret, Marie Noelle; Gelez, P.; Mura, Vincenzo La; Guillaud, Olivier; Majno, Pietro; Hadengue, Antoine; Morel, Philippe; Zarski, Jean Pierre; Fontana, Massimiliano; Moradpour, Darius; Mentha, Gilles; Boillot, Olivier; Leroy, Vincent; Giostra, Emiliano; Dumortier, Jérôme

doi:10.1111/j.1399-0012.2009.01121.x

Cited by 9 publications

(28 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of those with a history of IDU undergoing liver transplantation for HCV-related cirrhosis or HCC is 5–10% (De Gottardi et al, 2010; Robaeys et al, 2009). Relapse to drug use following transplantation is rare (De Gottardi et al, 2010; Robaeys et al, 2009).…”

Section: Liver Transplantationmentioning

confidence: 99%

“…Relapse to drug use following transplantation is rare (De Gottardi et al, 2010; Robaeys et al, 2009). Selection criteria for liver transplantation include: 6– 24 months of drug abstinence, controlled psychiatric disease and the presence of stable social support networks (Webb, Shepherd, & Neuberger, 2008).…”

Section: Liver Transplantationmentioning

confidence: 99%

“…Selection criteria for liver transplantation include: 6– 24 months of drug abstinence, controlled psychiatric disease and the presence of stable social support networks (Webb, Shepherd, & Neuberger, 2008). OST is not a contraindication (De Gottardi et al, 2010; Kanchana et al, 2002; Webb et al, 2008). There are no data in PWID.…”

Section: Liver Transplantationmentioning

confidence: 99%

See 2 more Smart Citations

Recommendations for the management of hepatitis C virus infection among people who inject drugs

Grebely

Robaeys

Bruggmann

et al. 2015

International Journal of Drug Policy

163

132

View full text Add to dashboard Cite

In high income countries, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). In many low and middle income countries large HCV epidemics have also emerged among PWID populations. The burden of HCV-related liver disease among PWID is increasing, but treatment uptake remains extremely low. There are a number of barriers to care which should be considered and systematically addressed, but should not exclude PWID from HCV treatment. The rapid development of interferon-free direct-acting antiviral (DAA) therapy for HCV infection has brought considerable optimism to the HCV sector, with the realistic hope that therapeutic intervention will soon provide near optimal efficacy with well-tolerated, short duration, all oral regimens. Further, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to enhance HCV assessment and treatment in this group are urgently needed. These recommendations demonstrate that treatment among PWID is feasible and provide a framework for HCV assessment and

show abstract

Section: Liver Transplantationmentioning

confidence: 99%

Section: Liver Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Recommendations for the management of hepatitis C virus infection among people who inject drugs

Grebely

Robaeys

Bruggmann

et al. 2015

International Journal of Drug Policy

163

132

View full text Add to dashboard Cite

show abstract

“…After liver transplant, patients with alcohol abuse have a 50% chance of relapse within 5 years 27 . In contrast, the rate of relapse to intravenous drug use after liver transplantation was extremely low, between 0% 29 and 3.4% 30 . Kidney transplant recipients have lower incidence of alcohol use disorder than general population 31 …”

Section: Background and Objectivesmentioning

confidence: 99%

“…These studies have been systematically reviewed elsewhere, 33,34 so we will only summarize the data. Risk factors for posttransplant relapse on alcohol and substance abuse include: female sex, 35 younger age, 36 psychiatric comorbidities, 30,32,37 personality disorder, 37 family history of alcoholism, 38 less than 6 months sobriety, a high‐risk alcoholism relapse score, 32 nonacceptance of alcohol problem and an abstinence of less than 3 months, 39 nicotine consumption at time of assessment, lack of insight into the alcohol dependence, 40 length of abstinence, number of admissions for alcohol withdrawal before transplantation, 41 continued alcohol use after liver disease diagnosis, no motivation for alcohol treatment, poor stress management skills, no rehabilitation relationship, limited social support, lack of nonmedical behavioral consequences, and continued engagement in social activities with alcohol present 42 …”

Section: Background and Objectivesmentioning

confidence: 99%

Systematic Review: Treatment for Addictive Disorder in Transplant Patients

Luchsinger

Zimbrean

2020

American J Addict

View full text Add to dashboard Cite

Background and Objectives The number of patients with substance use disorders in need for organ transplantation is expected to increase. Patients with addictive disorders are considered a higher risk of negative outcomes after organ transplantation due to the impact of substance use upon medical status and adherence with treatment. The goal of this systematic review was to assess the current literature on treatment for addiction transplant candidates and recipients. Methods We conducted a literature search within four databases PubMed, MEDLINE, EMBASE, and PsycINFO for publications dated 1/1/1988 to 12/31/2018. Results Out of 3108 articles identified through database screening, 39 were included in the qualitative synthesis. Sixteen studies described addiction treatment in groups over five patients. All the articles included liver transplant patients, with only two studies including patients who needed a kidney or a heart transplant. Nine articles described treatment of alcohol use disorder exclusively, five focused on treatment of opioid use disorders. Although 9 of 16 studies were prospective, the variability of the treatment intervention, outcome measures, and control group when applicable prohibited a meaningful meta‐analysis of the results. Eight articles that described the case reports are analyzed separately. Discussion and Conclusions Promising treatment options for alcohol use disorder have been reported but more studies are needed to confirm their effectiveness and their feasibility. Methadone appears effective for opioid disorder in transplant patients. Scientific Significance To the best of our knowledge, this is the first systematic review on the treatment of addictive disorders in transplant patients. (Am J Addict 2020;29:445–462)

show abstract

Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

Grebely

Robaeys

Bruggmann

et al. 2023

International Journal of Drug Policy

View full text Add to dashboard Cite

Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome

Abstract: Documented IDU was rare in liver transplanted patients. Past IDU was not associated with poorer survival after LT, and relapse after LT occurred in 3.4%.

Cited by 9 publications

References 15 publications

Recommendations for the management of hepatitis C virus infection among people who inject drugs

Recommendations for the management of hepatitis C virus infection among people who inject drugs

Systematic Review: Treatment for Addictive Disorder in Transplant Patients

Recommandations pour la prise en charge de l’infection par le virus de l’hépatite C chez les usagers de drogues par injection

Contact Info

Product

Resources

About